| Ytd | 29.83% | |
| 1y | -4.75% |
| Open | 10.68 | Prev Close | 10.83 | Low | 10.49 | High | 10.92 | Mkt Cap | 1.12B |
| Vol | 315.02K | Avg Vol | 1.61M | EPS | -1.44 | P/E | -7.52 | Forward P/E | -6.76 |
| Beta | 1.02 | Short Ratio | 11.29 | Inst. Own | 113.93% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-04 | 50-d Avg | 9.18 | 200-d Avg | 10.66 | 1yr Est | 20.29 |
ORIC News
ORIC Pharmaceuticals advances rinzimetostat into the global Phase 3 Himalayas-1 trial for mCRPC, wit
Enozertinib poster presentation to highlight data from an ongoing Phase 1b trial in first-line EGFR
Gainers Agape ATP (NASDAQ:ATPC) shares rose 17.5% to $2.96 during Wednesday's after-market sess
Initiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abirateron
Initiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abirateron
SOUTH SAN FRANCISCO and SAN DIEGO, July 02, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nas
Dow futures up 400 points; Bandwidth Inc (BAND) falls after $275M offering; other stocks declining i
ORIC Pharmaceuticals, Inc. (ORIC) Presents at Goldman Sachs 47th Annual Global Healthcare Conference
HC Wainwright & Co. analyst Robert Burns reiterates ORIC Pharmaceuticals (NASDAQ:ORIC) with a
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, June 05, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, I
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 27, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, In
NEW YORK, May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of invest
NEW YORK, May 14, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of invest
NEW YORK, May 7, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors o
Citigroup analyst Yigal Nochomovitz maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and l
Announced selection of rinzimetostat RP3D in combination with darolutamide for Himalayas-1 Phase 3 g
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 01, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, In
NEW YORK, April 30, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investor
NEW YORK, April 28, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inve
NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inve
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing tr
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 17, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals,
NEW YORK, April 16, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investor
LOS ANGELES--(BUSINESS WIRE)---- $ORIC--ORIC Investors Have Opportunity to Join ORIC Pharmaceuticals
HC Wainwright & Co. analyst Robert Burns reiterates ORIC Pharmaceuticals (NASDAQ:ORIC) with a
Shares of Oric Pharmaceuticals, Inc. (NASDAQ: ORIC) are tumbling Wednesday after the company announc
Wedbush analyst David Nierengarten maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Outperform
US stock futures higher with Dow up 200 pts, Beyond Meat shares drop after downbeat results; ORIC, R
NKE: -10% | Nike shares are trading lower after the company reported Q3 financial results. Also, the
Shares of nCino Inc (NASDAQ: NCNO) jumped 18% in pre-market trading after reporting strong Q4 result
ORIC Pharmaceuticals stock rose after reporting positive cancer drug data and advancing to a Phase 3
Rinzimetostat 400 mg once daily selected as RP3D in combination with darolutamide for Himalayas-1 gl
ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing t
HC Wainwright & Co. analyst Robert Burns reiterates ORIC Pharmaceuticals (NASDAQ:ORIC) with a
U.S. stock futures lower, with Dow futures down over 1%. BETA Technologies (NYSE: BETA) fell in pre-
Lisata Therapeutics (LSTA) surged 20.3% to $5.03 in pre-market trading after agreeing to be taken pr
U.S. stock futures lower, Dow down 100 points. Methanex (MEOH) shares fall 8.7% after reporting quar
Citigroup analyst Yigal Nochomovitz maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and r
HC Wainwright & Co. analyst Robert Burns maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a
Wedbush analyst David Nierengarten reiterates ORIC Pharmaceuticals (NASDAQ:ORIC) with a Outperfor
ORIC Pharmaceuticals (NASDAQ:ORIC) reported quarterly losses of $(0.30) per share which beat the ana
Wedbush analyst David Nierengarten reiterates ORIC Pharmaceuticals (NASDAQ:ORIC) with a Outperfor
Piper Sandler analyst Kelsey Goodwin initiates coverage on ORIC Pharmaceuticals (NASDAQ:ORIC) wit
Wells Fargo analyst Derek Archila maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Overweight